Suppr超能文献

术后观察与放疗用于病理 N1 口腔鳞状细胞癌。

Postoperative Observation Versus Radiotherapy for Pathologic N1 Oral Cavity Squamous Cell Carcinoma.

机构信息

Department of Radiation Oncology, University of California, Los Angeles.

Palo Alto Veterans Affairs Hospital, Palo Alto, CA.

出版信息

Am J Clin Oncol. 2021 Mar 1;44(3):99-104. doi: 10.1097/COC.0000000000000792.

Abstract

OBJECTIVES

To investigate the benefit of postoperative radiotherapy (PORT) for low-volume (pN1) nodal disease after resection of oral cavity squamous cell carcinoma.

MATERIALS AND METHODS

The National Cancer Database was queried for adults with nonmetastatic squamous cell carcinoma of the oral cavity treated by surgical resection with pathologic stage T1-2 N0-2 (American Joint Committee on Cancer 7th edition) and with the maximal exclusion of standard indications for PORT. Overall survival was compared within pN1 for observation versus PORT and then compared for pN1 versus pN0 and versus pN2 stratified by receipt of observation or PORT. Multivariable Cox regression was used to adjust for potential confounders between PORT and survival, including comorbidity and age.

RESULTS

Overall 5017 pN0, 530 pN1, and 253 pN2 patients were identified, of whom 9%, 35%, and 64% received PORT, respectively. Within the pN1 cohort, PORT was associated with improved survival versus observation (adjusted hazard ratio, 0.66; 95% confidence interval, 0.46-0.97; P=0.03). Among observed patients, the prognosis of pN1 was equivalent to pN2 and inferior to pN0; in contrast, among patients treated with PORT, the prognosis of pN1 was equivalent to pN0 and superior to pN2. Without PORT, pN1 remained an adverse risk factor relative to pN0 regardless of the depth of invasion, lymph node size, lymph node location, and extent of lymph node dissection.

CONCLUSIONS

PORT was associated with a survival benefit compared with observation. Notably, pN1 was an adverse risk factor relative to pN0 if, and only if, patients did not receive PORT, suggesting pN1 by itself may be an indication for PORT.

摘要

目的

探讨口腔鳞状细胞癌切除术后低容量(pN1)淋巴结疾病行术后放疗(PORT)的获益。

材料与方法

本研究在美国国家癌症数据库中检索了经手术切除治疗、病理分期为 T1-2 N0-2(美国癌症联合委员会第 7 版)且排除 PORT 标准适应证的最大局限性的非转移性口腔鳞状细胞癌成年患者。对观察与 PORT 治疗下的 pN1 患者的总生存率进行了比较,然后对 pN1 与 pN0 以及 pN2 患者(根据是否接受观察或 PORT 治疗进行分层)进行了比较。多变量 Cox 回归用于调整 PORT 与生存之间的潜在混杂因素,包括合并症和年龄。

结果

共确定了 5017 例 pN0、530 例 pN1 和 253 例 pN2 患者,分别有 9%、35%和 64%的患者接受了 PORT。在 pN1 队列中,与观察相比,PORT 治疗与生存率提高相关(调整后的危险比为 0.66;95%置信区间为 0.46-0.97;P=0.03)。在观察患者中,pN1 的预后与 pN2 相当,劣于 pN0;相比之下,在接受 PORT 治疗的患者中,pN1 的预后与 pN0 相当,优于 pN2。如果患者未接受 PORT,pN1 仍然是相对于 pN0 的不良危险因素,而与肿瘤浸润深度、淋巴结大小、淋巴结位置和淋巴结清扫范围无关。

结论

与观察相比,PORT 治疗与生存获益相关。值得注意的是,如果患者未接受 PORT,pN1 相对于 pN0 是一个不良危险因素,这表明 pN1 本身可能是 PORT 的适应证。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验